【医学课件】hps研究课件.ppt

HPS: Heart Protection Study
Purpose
To determine whether simvastatin reduces mortality and vascular events in patientsents
Men
Women
History of coronary disease
Previous MI
Other
Other risk factors in absence of
coronary diseasea
Baseline characteristics
20,536
15,454
5082
8510
4876
7150
No.
75
25
41
24
35
Cerebrovascular disease
Peripheral arterial disease
Diabetes mellitus
1820
2701
3982
9
13
19
% of total
a
Some patients had more than one of these conditions.
HPS Collaborative Group.
Lancet
2002;
360
:7
Ð
22.
HPS: Heart Protection Study- RESULTS -
All-cause mortality in simvastatin group significantly reduced compared with placebo ( vs. %, P<); reduction was attributed largely to significant reduction in coronary death:
Other vascular death reduced but with marginal significance
Nonvascular death reduced but not significantly
First major vascular event rate significantly reduced, as were the individual event rates (fatal/nonfatal MI, fatal/nonfatal stroke, and revascularization)
No difference in new cancers ( vs %, rate ratio , P=) except nonmelanoma skin cancer ( vs %)
No difference in withdrawal due to myopathy (% in both groups)
HPS: Heart Protection Study- RESULTS continued -
Vascular causes
Coronary
Other vascular
Subtotal: any vascular
Non-vascular causes
Neoplastic
Respirator